**Table 1. Demographic characteristics and severity of acute ischemic stroke in the patients who received systemic thrombolytic therapy**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Parameter** | **Women (N = 102)** | **Men (N = 107)** | **Р value** | **Total (N = 209)** |
| Age, years | 67.3 ± 11.3 | 62,2 ± 12.2 | 0.003 | 64.7 ± 12.0 |
| Primary/secondary IS, n | 70/32 | 82/25 | 0.194 | 152/57 |
| Pathogenetic subtype of IS, n |
| atherothrombotic | 35 | 48 |  | 83 |
| cardioembolic | 32 | 31 |  | 63 |
| lacunar | 8 | 3 |  | 11 |
| unidentified | 27 | 25 |  | 52 |
| The time period from the symptom onset to the beginning of STLT, min | 162.3 ± 52.0 | 155,1 ± 43.0 | 0.289 | 158.6 ± 47.6 |
| NIHSS score, day 0 | 10.0 [8.0; 15.0] | 11.0 [9.0; 15.0] | 0.517 | 11.0 [8.0; 15.0] |
| mRS score, day 0 | 4.0 [4.0; 5.0] | 4.0 [4.0; 5.0] | 0.362 | 4.0 [4.0; 5.0] |
| Hemorrhagic transformation of the IS focus, n (%) | 12 (11.8) | 17 (15.9) | 0.107 | 29 (13.9) |
| Mortality rate, n (%) | 12 (11.8) | 18 (16.8) | 0.298 | 30 (14.4) |

IS, ischemic stroke; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; STLT, systemic thrombolytic therapy

Continuous data are given as means and standard deviations (M ± SD), categorical data, as medians and quartiles (Me [Q1; Q3])

**Table 2. Efficacy of systemic thrombolytic therapy in surviving patients**

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter** | **Women (n = 90)** | **Men (n = 89)** | **P value** |
| Age, years | 65.7 ± 11.0 | 60.8 ± 12.0 | 0.008 |
| NIHSS score, Day 28 | 3.0 [1.0; 5.0] | 3.0 [1.0; 6.0] | 0.129 |
| Regress by NIHSS, scores | 6.0 [5.0; 10.0] | 6.0 [4.0; 9.0] | 0.318 |
| mRS score, Day 28 | 2.0 [1.0; 3.0] | 2.0 [1.0; 3.0] | 0.496 |
| Regress by mRS, scores | 2.0 [1.0; 3.0] | 2.0 [1.0; 3.0] | 0.496 |
| Glucose, mmol/L | 6.7 [5.3; 7.9] | 5.9 [4.9; 7.0] | 0.017 |
| Type 2 diabetes mellitus, n (%) | 29 (32.2) | 17 (19.1) | 0.045 |
| Arterial hypertension, n (%) | 79 (87.8) | 71 (79.8) | 0.147 |
| Atrial fibrillation, n (%) | 37 (41.1) | 31 (34.8) | 0.387 |
| Body mass index, kg/m2 (min.-max.) | 30.9 ± 4.2 (23.8–44.1) | 30.3 ± 4.8 (21.1–52.6) | 0.421 |

mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale

Continuous data are given as means and standard deviations (M ± SD), categorical data, as medians and quartiles (Me [Q1; Q3])

**Table 3. Systemic thrombolytic therapy efficacy in the patients with atrial fibrillation**

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter** | **Women (n = 42)** | **Men (n = 42)** | **P value** |
| Proportion of patients with AF, % (n/N) | 46.7 (42/90) | 47.2 (42/89) | 0.317 |
| Age, years | 65.7 ± 11.0 | 67.8 ± 8.7 | 0.046 |
| Pathogenetic subtype of IS, n |
| atherothrombotic | 8 | 6 |  |
| cardioembolic | 32 | 29 |  |
| lacunar | 2 | 1 |  |
| unidentified | 0 | 6 |  |
| The time period from the symptom onset to the beginning of STLT, min | 161.9 ± 53.0 | 142,7 ± 40.7 | 0.088 |
| NIHSS score, Day 0 | 10.0 [9.0; 16.25] | 12.0 [9.25; 18.5] | 0.243 |
| NIHSS score, Day 28\* | 4.0 [2.0; 7.0] | 4.0 [2.0; 9.0] | 0.568 |
| Regress by NIHSS, scores\* | 6.0 [5.0; 10.0] | 7.0 [4.0; 9.5] | 0.858 |
| mRS score, Day 0 | 5.0 [4.0; 5.0] | 4.0 [4.0; 5.0] | 0.234 |
| mRS score, Day 28\* | 3.0 [1.0; 4.0] | 3.0 [1.0; 5.75] | 0.394 |
| Regress by mRS, scores\* | 2.0 [1.0; 3.0] | 2.0 [1.0; 3.0] | 0.923 |
| Glucose, mmol/L (min.-max.) | 8.5 ± 3.5 (4.4–15.9) | 7.0 ± 2.6 (3.5–14.3) | 0.06 |
| Type 2 diabetes mellitus, n (%) | 17 (40.5) | 9 (21.4) | 0.05 |
| Arterial hypertension, n (%) | 37 (88.1) | 40 (95.2) | 0.151 |
| Symptomatic hemorrhagic transformation, n (%) | 5 (11.9) | 10 (23.8) | 0.155 |
| Body mass index, kg/m2 (min.-max.) | 29.9 ± 3.5 (24.2–40.4) | 30.3 ± 4.0 (21.8–38.7) | 0.663 |
| Mortality rate, n (%) | 5 (11.9) | 11 (26.6) | 0.096 |

AF, atrial fibrillation; IS, ischemic stroke; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; STLT, systemic thrombolytic therapy

Continuous data are given as means and standard deviations (M ± SD), categorical data, as medians and quartiles (Me [Q1; Q3])

\* In those alive by Day 28

**Table 4. The criteria for metabolic syndrome in the patients with ischemic stroke who received systemic thrombolytic therapy**

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter, n (%)** | **Women (N = 102)** | **Men (N = 107)** | **χ2 (p value for between-group comparison)** |
| Increased waist circumference | 89 (87.3) | 86 (80.4) | 1.815 (p = 0.178) |
| Increased triglyceride levels | 68 (66.7) | 36 (33.6) | 22.778 (p < 0.001) |
| Decreased HDL cholesterol levels | 72 (70.6) | 35 (32.7) | 29.986 (p < 0.001) |
| Arterial hypertension | 89 (87.3) | 94 (87.9) | 0.017 (p = 0.897) |
| Hyperglycemia/T2DM | 91 (89.2) | 66 (61.7) | 21.181 (p < 0.001) |
| One main and two additional criteria of the metabolic syndrome | 94 (92.2) | 71 (66.4) | 24.426 (p < 0.001) |

HDL, high density lipoprotein; T2DM, type 2 diabetes mellitus